Tirzepatide, the active ingredient in both Mounjaro for type 2 diabetes and Zepbound for weight loss, was in short supply for more than two years. But the drugmaker Eli Lilly is “currently meeting or exceeding demand” for all doses of these medicines and should continue to do so going forward, the FDA said in a December 19 statement.

Up to a third of the weight lost while taking weight loss jabs such as Wegovy and Mounjaro includes muscle and bone mass.

Eli Lilly & Co.’s diabetes and weight-loss drugs Mounjaro and Zepbound are no longer in short supply in the US, which means compounding pharmacies must stop making less expensive copycat versions in the coming months.

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity.

Around the holidays – when many people are baking cookies for Santa, enjoying cocktail parties or having festive family feasts – some adults who use popular medications for diabetes or weight loss might explore skipping a dose for a week or two because they want to fully delight in their favorite foods,

The finding effectively bars widespread sales of cheaper copies of the drugs that many patients use, but the FDA said it would not take any action against the compounding pharmacies